TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Galmed Pharmaceuticals ( (GLMD) ) has shared an announcement.
On August 28, 2025, Galmed Pharmaceuticals announced its financial results for the second quarter of 2025, reporting a net loss of $2.5 million compared to $1.1 million in the same period in 2024. The company has adopted a digital asset management strategy, potentially allocating up to 50% of its cash reserves to digital assets, and has terminated a previous agreement with Entomus s.r.o. for a drug delivery system, opting instead to invest in a new UK-based company for its development.
Spark’s Take on GLMD Stock
According to Spark, TipRanks’ AI Analyst, GLMD is a Underperform.
Galmed Pharmaceuticals faces significant financial challenges, with no revenue and continuous losses, which heavily impact its stock score. Poor technical indicators and negative valuation metrics further weigh down the score. The strong equity position offers some support but is overshadowed by the lack of operational efficiency and profitability.
To see Spark’s full report on GLMD stock, click here.
More about Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company based in Israel, focusing on the development of Aramchol for liver diseases and expanding into oncological indications. The company is also pursuing opportunities to diversify its product pipeline, targeting cardiometabolic diseases and leveraging its expertise in drug development.
Average Trading Volume: 302,988
Technical Sentiment Signal: Sell
Current Market Cap: $7.62M
For a thorough assessment of GLMD stock, go to TipRanks’ Stock Analysis page.